Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
Por um escritor misterioso
Descrição
Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies
Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation - Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy
Capturing adaptive immunity against SARS-CoV-2 in patients with cancer
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Cancers, Free Full-Text
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Immunity to SARS‐CoV‐2 induced by infection or vaccination - Castro Dopico - 2022 - Journal of Internal Medicine - Wiley Online Library
Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation
COVID-19 in patients with hematologic malignancy - ScienceDirect
COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19: Molecular Therapy
Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
de
por adulto (o preço varia de acordo com o tamanho do grupo)
